Published in Molecular Psychiatry, the research examined molecular and electrical changes associated with rapid-acting antidepressants in laboratory models and in data from a previous clinical trial. The investigators found that several compounds produced a shared pattern of immune-related activity in brain cells. In patients treated with ketamine, similar changes appeared in blood-based immune signals and in brain-wave activity, providing evidence that the response may involve coordinated changes throughout the body rather than a process confined to the brain.

Treatment-resistant depression is generally diagnosed when depressive symptoms persist despite multiple courses of conventional antidepressants or psychotherapy. Traditional medications often require weeks to produce noticeable effects, and many patients receive little or no benefit. Ketamine and psilocybin have attracted intense scientific attention because they can reduce symptoms rapidly in some people with difficult-to-treat depression. However, clinicians currently have few reliable biological indicators that can predict who will respond before treatment begins.

The new study focused on signaling pathways involving interleukin-7, or IL-7, and interleukin-15, or IL-15. Interleukins are small proteins used by immune cells to communicate and regulate inflammation, cell survival and the development of specific immune-cell populations. Although these molecules are best known for their role in immunology, immune signals can also influence neural function by affecting brain cells, blood vessels and the activity of neural circuits. This two-way interaction, often called neuroimmune communication, is increasingly viewed as relevant to depression and other psychiatric disorders.

In the clinical data, patients who responded to ketamine showed lower activity in the IL-15 pathway and stronger B-cell signaling before treatment than patients who failed to respond. B cells are immune cells involved in antibody production and broader immune regulation. After ketamine treatment, these patterns shifted in responders: IL-15-related activity and B-cell signaling moved toward a different balance. The researchers interpret the results as evidence that successful rapid antidepressant treatment may involve the restoration of equilibrium between IL-7 and IL-15 signaling.

The team also examined gamma power, a pattern of high-frequency electrical activity in the brain. Gamma activity is associated with the coordination of neural networks and the formation or strengthening of connections between brain regions. In patients with high IL-7 activity before treatment, brain-wave patterns differed from those observed after ketamine administration. The parallel movement of immune markers in the blood and gamma activity in the brain suggests that peripheral immune biology may be linked to changes in neural connectivity during antidepressant response.

The study does not suggest that ketamine or psychedelics directly act as immune therapies, nor does it establish that IL-7 or IL-15 causes depression or determines treatment response on its own. Instead, the findings point to a network of interacting biological processes. Ketamine is known to influence glutamate signaling and synaptic plasticity, while classic psychedelics primarily act on serotonin receptors, especially the 5-HT2A receptor. The researchers propose that these distinct mechanisms may converge downstream on immune-related pathways that support changes in neural plasticity and circuit function.

“Ketamine and psychedelics affect the brain in different ways subjectively, but our findings suggest that they eventually end up in some of the same neuroimmune pathways,” said Gregory Jones, M.D., assistant professor of Psychiatry at MD Anderson and co-leader of the study. He noted that combining blood-based measurements with brain-activity data could give researchers a clearer picture of how the body and brain cooperate during antidepressant treatment, including in people coping with depression after a cancer diagnosis.

The results remain exploratory and require confirmation in larger, prospective clinical studies. Future research will need to determine whether IL-7, IL-15, B-cell signals or related molecular patterns can predict response before therapy, rather than simply reflecting changes after treatment has occurred. Scientists will also need to establish how long these biological shifts last, whether they are specific to ketamine and psychedelics, and whether they correlate with durable symptom relief. If validated, such biomarkers could eventually help clinicians select treatments more efficiently and identify biological targets for extending the benefits of rapid-acting antidepressants. The work was supported in part by the National Institutes of Health.

Subject of Research: People

Article Title: Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics

News Publication Date: 30 July 2026

Web References: https://www.mdanderson.org/ ; https://www.nature.com/articles/s41380-026-03777-z

References: Molecular Psychiatry, DOI: 10.1038/s41380-026-03777-z

Image Credits: The University of Texas MD Anderson Cancer Center

Keywords: treatment-resistant depression, ketamine, psilocybin, psychedelics, rapid-acting antidepressants, neuroimmune signaling, IL-7, IL-15, B cells, gamma brain waves, biomarkers, psychiatry

Depression’s heterogeneity manifests not only in symptom presentation but also in how patients respond to treatment. Approximately half of those diagnosed with depression do not experience relief from first-line therapies, which typically include various pharmacological and psychotherapeutic interventions. These sobering statistics underscore the urgent need for improved methods to predict which treatments will most effectively alleviate symptoms in distinct patient subgroups. This ambitious international project seeks to harness data-driven insights to construct a robust clinical decision support tool, designed to provide clinicians and patients with personalized treatment recommendations grounded in comprehensive patient data.

The study, recently published in the esteemed journal PLOS One, outlines the protocol for developing a sophisticated multivariable prediction model. Unlike traditional trials that analyze treatment efficacy in isolation, this initiative integrates individual participant data from over 60 randomized controlled trials worldwide, encompassing nearly 10,000 adults diagnosed with depression. By pooling such an extensive dataset, the researchers aspire to overcome sample size limitations that have historically impeded the development of reliable, generalizable clinical prediction models.

Central to this research is the concept that treatment efficacy may be significantly influenced by patient-specific characteristics, including demographic variables such as age and gender, as well as clinical factors like the presence of comorbid psychiatric disorders—anxiety and personality disorders among them. Prior attempts at treatment selection have often neglected this intricate interplay of factors, focusing instead on single or limited variables. The team’s multidimensional analytic framework leverages network meta-analysis methodologies to simultaneously evaluate the relative effectiveness of five major empirically supported treatments: antidepressant medications, cognitive therapy, behavioral therapy, interpersonal therapy, and short-term psychodynamic therapy.

The painstaking data curation process itself represents a monumental scientific achievement. Over five years were dedicated solely to cleaning, harmonizing, and integrating disparate datasets collected from international collaborators spanning numerous institutions and research disciplines. This meticulous groundwork ensures that subsequent predictive models rest on a foundation of high-quality, standardized data that accurately reflects the complex reality of clinical depression treatment outcomes.

Ellen Driessen, the study’s lead researcher, emphasizes the importance of examining the influence of comorbid conditions on treatment response. Their hypothesis posits that certain subpopulations may derive a greater benefit from specific therapeutic modalities. For example, patients exhibiting prominent anxiety symptoms alongside depression might respond differently to behavioral therapy compared to pharmacological interventions. Exploring these nuances is vital to dismantling the one-size-fits-all paradigm that currently dominates clinical practice.

The envisioned clinical decision support tool will embody this precision medicine ethos. By inputting a patient’s unique clinical and demographic profile, clinicians will receive tailored treatment recommendations, effectively streamlining the decision-making process and maximizing the likelihood of therapeutic success. Unlike existing clinical guidelines that offer broad, generalized advice, this tool promises dynamic, patient-specific guidance derived from empirical evidence aggregated across diverse populations and treatment contexts.

Zachary Cohen, senior author and assistant professor at the University of Arizona’s Department of Psychology, highlights the transformative potential of such a tool for clinical practice worldwide. Notably, the variables incorporated into the model are largely accessible via standard self-report questionnaires and routine demographic assessments, mitigating resource barriers that have traditionally limited the applicability of personalized medicine approaches in mental health. This accessibility, paired with the anticipated low cost of implementation, positions the tool as a scalable solution for healthcare systems globally.

Looking ahead, the research group plans to initiate prospective clinical trials to validate the tool’s efficacy in real-world clinical environments. These investigations will assess whether integrating the decision support system into routine care indeed improves patient outcomes, optimizes resource allocation, and reduces the protracted trial-and-error period that many individuals endure. Success in these trials could hasten widespread adoption and integration into electronic health records or web-based platforms.

Beyond individual patient benefits, the broader societal implications are substantial. Depression imposes immense personal suffering and economic burden, including lost productivity and healthcare costs. Streamlining treatment selection to enhance efficiency and effectiveness could alleviate these challenges on a systemic level, marking a paradigm shift in mental health care.

Moreover, this international collaborative effort exemplifies the power of interdisciplinary science in addressing complex medical challenges. By combining expertise in psychology, psychiatry, statistics, data science, and clinical practice, the team has fashioned a comprehensive approach capable of capturing the multifaceted nature of depression and its treatments. This approach may serve as a blueprint for precision medicine development in other psychiatric and medical domains.

While the current publication primarily delineates the study’s protocol, the authors acknowledge that the actual construction and refinement of the predictive tool are forthcoming. These stages will undoubtedly entail rigorous algorithm development, validation, and user-interface design, ensuring that the final product is both scientifically robust and clinically practical.

In sum, this pioneering study represents a critical stride toward individualized depression care, promising to enhance therapeutic outcomes through data-driven, evidence-based recommendations. As research progresses, the mental health community and patients worldwide may soon benefit from treatment strategies that recognize and respond to their unique clinical profiles, transforming depression care from a guessing game into a precise, personalized science.

Subject of Research: People

Article Title: Developing a multivariable prediction model to support personalized selection among five major empirically-supported treatments for adult depression. Study protocol of a systematic review and individual participant data network meta-analysis

News Publication Date: 23-Apr-2025

Web References:
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0322124
http://dx.doi.org/10.1371/journal.pone.0322124

Keywords: Depression, personalized treatment, clinical decision support tool, precision medicine, randomized controlled trials, psychiatric comorbidity, psychotherapy, antidepressant medications, data harmonization, individualized care, network meta-analysis, mental health